Amylin Pharmaceuticals and Biocon, Ltd. have entered into an exclusive agreement to develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. The two companies will collaborate to develop the compound using Amylin’s phybrid technology and will share development costs. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. Amylin will provide expertise in pe...